<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1140">
  <stage>Registered</stage>
  <submitdate>25/02/2006</submitdate>
  <approvaldate>1/03/2006</approvaldate>
  <actrnumber>ACTRN12606000085572</actrnumber>
  <trial_identification>
    <studytitle>Dexmedetomidine and Haloperidol for the management of emergence delirium in intensive care</studytitle>
    <scientifictitle>Dexmedetomidine and Haloperidol for the management of emergence delirium in intensive care</scientifictitle>
    <utrn />
    <trialacronym>DeHedic</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Delirium in mechanically ventilated intensive care patients</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients will be randomised to receive IV Haloperidol 5 mg 6 hourly after loading</interventions>
    <comparator>Patients will be randomised to receive IV Dexmedetomidine 0.4 to 1.0 mcg/kg/hr for up to 7 days</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>1. Number of patients extubated</outcome>
      <timepoint>Within 36 hours of enrolment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>2. Percentage of patients scoring 0 to + 1 on the Prince of Wales sedation score (POWSS) or a negative Confusion Assessment Method (CAM)</outcome>
      <timepoint>At 36 hours of enrolment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Time to extubation in ICU</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Use of physical restraints in ICU</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. The difference in 24 hour urinary  catecholamine</outcome>
      <timepoint>At day 1 and 3.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4. Time to ready for discharge from ICU.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>5. Re admission to intensive care during hospital stay.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>6. Any additional drugs needed during study period including;
a. Haloperidol in the Dexmedetomidine arm.
b. Midazolam and or Propofol.
c. Other antipsychotics.
d. ÃŸ blockers</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>7. Re-intubation</outcome>
      <timepoint>Within 24 hours.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>8. Accidental extubation in ICU.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>9. Accidental removal of other catheters in ICU.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>10. Introduction of a new vasoactive drug during study period i.e. inotropes or pressor.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>11. Hospital outcome.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>12. Number of CT scans for neurological evaluation in ICU.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Patient requiring invasive ventilation for longer than 24 hours. 2. Receiving narcotics and /or sedatives for longer than 24 hours. 3. Development of clinical agitation and/or delirium upon weaning narcotics and/or sedatives on commencement of weaning from mechanical ventilation as per the POWSS. 4. Informed consent signed by person responsible within 24 hours of enrolment.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Allergy to any of the trial drugs.2. Patients who are or likely to be pregnant or lactating.3. Any patient with a Body Mass Index of &gt;304. Patients receiving other long term alpha 2 agonists.5. Involvement in a sedation study within the last 30 days.6. Known opiate or benzodiazepines dependence, treatment for chronic pain or recent detoxification therapy within the last 6 months. 7. Patients on anti-psychotic drugs  8. Known dementia, Parkinsonism or epilepsy.9. Patients with recent cerebro-vascular surgery or traumatic brain injury.10. Any evidence of critical illness polyneuropathy.11. Patient with a recent tracheostomy.12. Recent surgery involving free flap.13. Haemodynamically unstable patients with Systolic blood pressure &lt; 90 mmHg and or Heart rate &lt; 55 / min.14. Patients on CVVHD.15. Patients with hepatic encephalopathy within 14 days.16. Patients with a recent drug overdose or CO poisoning.17. Patients who are Non-English Speaking background.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Randomised sealed envelopes</concealment>
    <sequence>computer generated numbers</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/03/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Prince of Wales Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Prince of Wales Hospital</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital ethics</ethicname>
      <ethicaddress />
      <ethicapprovaldate>23/11/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Yahya Shehabi</name>
      <address>Intensive Care Unit
Prince of Wales Hospital
Level 1
Dickinson Building
Barker St
Randwick NSW 2031</address>
      <phone>+61 2 93824721</phone>
      <fax />
      <email>yshehabi@ozemail.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Naomi Hammond</name>
      <address>Intensive Care Unit
Prince of Wales Hospital
Level 1
Dickinson Building
Barker St
Randwick NSW 2031</address>
      <phone>+61 2 93824720</phone>
      <fax />
      <email>naomi.hammond@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>